Holen Sie sich die Stockscreener-App
79.03
2.03%
1.53
Handel nachbörslich:
79.03
Schlusskurs vom Vortag:
$77.50
Offen:
$78.18
24-Stunden-Volumen:
416.87K
Relative Volume:
0.42
Marktkapitalisierung:
$6.45B
Einnahmen:
$58.89M
Nettoeinkommen (Verlust:
$-240.88M
KGV:
-25.49
EPS:
-3.1
Netto-Cashflow:
$-239.96M
1W Leistung:
-5.29%
1M Leistung:
-3.97%
6M Leistung:
+68.27%
1J Leistung:
+136.38%
1-Tages-Spanne:
$77.10
$81.25
1-Wochen-Bereich:
$76.85
$86.92
52-Wochen-Spanne:
$19.45
$103.00
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Firmenname
Kymera Therapeutics Inc
Sektor
Branche
Telefon
857-285-5314
Adresse
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
79.03 | 6.33B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-06 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | Fortgesetzt | Guggenheim | Buy |
| 2025-10-24 | Bestätigt | B. Riley Securities | Buy |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-20 | Fortgesetzt | Stifel | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-12-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-26 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Eingeleitet | Truist | Buy |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-08-03 | Eingeleitet | Goldman | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | JP Morgan | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2021-09-30 | Eingeleitet | B. Riley Securities | Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-09-15 | Eingeleitet | BofA Securities | Neutral |
| 2020-09-15 | Eingeleitet | Cowen | Outperform |
| 2020-09-15 | Eingeleitet | Guggenheim | Buy |
| 2020-09-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Kymera at Barclays Conference: Strategic Focus on Immunology By Investing.com - Investing.com Canada
Kymera Therapeutics CFO presents new immunology strategy at Barclays Healthcare Conference - Traders Union
Kymera Therapeutics, Inc. $KYMR Holdings Trimmed by Atika Capital Management LLC - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 25,758 Shares - MarketBeat
Hedge Fund Moves: Can Kymera Therapeutics Inc weather a recessionVolume Spike & Daily Chart Pattern Signals - baoquankhu1.vn
Kymera to present atopic dermatitis trial data at AAD meeting By Investing.com - Investing.com Canada
Kymera at Leerink Global Healthcare: Strategic Insights on Drug Development By Investing.com - Investing.com Canada
KYMR: KT-621 shows strong early efficacy and safety; pivotal Phase 2b readouts expected in 2027 - TradingView
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology Annual Meeting - Investing News Network
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting - Bitget
Experimental atopic dermatitis pill KT-621 heads to late-breaking AAD stage - Stock Titan
A Look At Kymera Therapeutics (KYMR) Valuation After Equity Raise, Wider Losses And Leadership Change - Sahm
Kymera CEO Nello Mainolfi’s Boldest Line Had Nothing to Do With the Earnings Miss - Yahoo Finance
Market Moves: What is the long term forecast for Kymera Therapeutics Inc. stockWeekly Profit Report & Safe Capital Growth Plans - baoquankhu1.vn
How (KYMR) Movements Inform Risk Allocation Models - Stock Traders Daily
Kymera Therapeutics (NASDAQ:KYMR) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Profit Recap: How sensitive is Kymera Therapeutics Inc to inflationWeekly Volume Report & Reliable Entry Point Trade Alerts - baoquankhu1.vn
JPMorgan Chase & Co. Has $10.91 Million Stock Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Q1 EPS Estimate for Kymera Therapeutics Boosted by Analyst - MarketBeat
Kymera (KYMR) Q4 2025 Earnings Call Transcript - AOL.com
Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 3,919 Shares - MarketBeat
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CFO Sells 4,895 Shares of Stock - MarketBeat
Kymera Stock Up 130% as $135 Million Buy Boosts Immunology Bet - AOL.com
Bruce Jacobs Sells 7,576 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Jared Gollob Sells 5,613 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 81,866 Shares of Stock - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Acquired by Rafferty Asset Management LLC - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $128.00 - MarketBeat
UBS Raises Price Target for Kymera Therapeutics (KYMR) to $128 | - GuruFocus
Kymera at TD Cowen Conference: Strategic Insights on Drug Programs - Investing.com
Commit To Purchase Kymera Therapeutics At $60, Earn 15.1% Annualized Using Options - Nasdaq
How Kymera’s Bigger Losses and New Equity Plans May Impact Kymera Therapeutics (KYMR) Investors - simplywall.st
Kymera Therapeutics (KYMR) Stock Analysis: Exploring a 30% Upside Potential Amid Biotech Innovation - DirectorsTalk Interviews
UBS Adjusts Price Target on Kymera Therapeutics to $128 From $90, Maintains Buy Rating - marketscreener.com
Kymera Therapeutics: Well-Funded Pipeline Enters A Defining Clinical Phase (NASDAQ:KYMR) - Seeking Alpha
Kairos Pharma signs deal for Celyn Therapeutics’ CL-273 - Pharmaceutical Technology
Citigroup Raises Kymera Therapeutics (NASDAQ:KYMR) Price Target to $120.00 - MarketBeat
Kymera Therapeutics (KYMR): Citigroup Raises Price Target, Reaff - GuruFocus
Stephens raises Kymera Therapeutics price target to $100 on pipeline By Investing.com - Investing.com Canada
Kymera Therapeutics (KYMR): Analyst Raises Price Target to $100 | KYMR Stock News - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $100.00 at Stephens - MarketBeat
TD Asset Management Inc Reduces Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
The Bull Case For Kymera Therapeutics (KYMR) Could Change Following Wider Losses And Major Equity Plans - Yahoo Finance
Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029 - MarketBeat
Kymera Therapeutics Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Vanguard Group Inc. Cuts Stake in Kymera Therapeutics, Inc. $KYMR - MarketBeat
KYMR Should I Buy - Intellectia AI
Kymera Therapeutics (KYMR) TTM Loss Of US$311 Million Tests Bullish Growth Narrative - simplywall.st
Kymera Therapeutics Signals Strong Momentum In Earnings Call - TipRanks
Kymera Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:KYMR) 2026-02-27 - Seeking Alpha
Kymera’s KT-579 Enters First-in-Human Testing: What Early Trial Progress Means for Investors - TipRanks
Finanzdaten der Kymera Therapeutics Inc-Aktie (KYMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):